Soleno Therapeutics, Inc.
NCM: SLNOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Soleno Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SLNO Z-Score →About Soleno Therapeutics, Inc.
Healthcare
Biotechnology
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
📊 Fundamental Analysis
Soleno Therapeutics, Inc. demonstrates a profit margin of 11.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is 6.0%, which suggests room for improvement in capital utilization.
At a current price of $52.63, SLNO currently sits at the 38th percentile of its 52-week range (Range: $29.43 - $90.32).
💰 Valuation Insight
SLNO trades at a 439.8% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$2.72B
Trailing P/E
134.95
Forward P/E
-23.19
Beta (5Y)
-2.81
52W High
$90.32
52W Low
$29.43
Avg Volume
3.15M
Day High
Day Low